article
Issue #3 2015 – Digital edition
In Issue #3 2015: Regulatory Insight, Microfluidics, PCR in-depth focus, Drug Delivery, Content Uniformity, HPLC, Microbiology in-depth focus, NMR, PAT and much more...
List view / Grid view
Formulation
news
Global biosimilars market value could hit $55 billion by 2020, says GBI Research
30 June 2015 | By Victoria White
The global biosimilars market value is expected to reach $20 billion by the end of 2015 and could hit $55 billion by 2020, according to GBI Research...
news
Mayor of London considers £10bn ‘megafund’ as option to boost drug development
25 June 2015 | By Victoria White
Plans to create a £10bn megafund that would make it easier for drug development will be discussed at a conference hosted by the Mayor of London’s Office...
news
Quotient Clinical delivers breakthrough first-in-human program for Corcept Therapeutics
10 June 2015 | By kdm communications
Quotient Clinical, the Translational Pharmaceutics® Company, has announced the successful completion of an Enabled-First-in-Human® (Enabled-FIH) program for US biotech company Corcept Therapeutics Incorporated...
news
Phase 2a clinical trial results for emixustat hydrochloride published
4 June 2015 | By Victoria White
Results from a Phase 2a clinical trial of emixustat in geographic atrophy associated with dry age-related macular degeneration have been published...
news
Faron and CMS enter into strategic agreement for the development of Traumakine in China, Hong Kong, Macao and Taiwan
26 May 2015 | By Victoria White
Faron has entered into strategic agreements with CMS and A&B Ltd for the development and commercialisation of Traumakine for the treatment of ARDS...
news
Clinical data on EBI-005 for the treatment of dry eye disease and allergic conjunctivitis presented at ARVO 2015
8 May 2015 | By Victoria White
Eleven Biotherapeutics presented clinical data for EBI-005 for dry eye disease and allergic conjunctivitis at the ARVO 2015 Annual Meeting...
article
Issue #2 2015 – Digital edition
In Issue #2 2015: Outsourcing, Drug pricing reforms, Stem Cells in-depth focus, Microbiology series, Environmental monitoring, LC-MS in-depth focus, Manufacturing solutions, PAT series and much more...
news
Updated results from Phase 1/2 clinical trial evaluating TPI 287 for treatment of recurrent glioblastoma announced
22 April 2015 | By Victoria White
Cortice Biosciences has announced interim results a Phase 1/2 trial evaluating TPI 287 plus bevacizumab for the treatment of glioblastoma multiforme...
news
Early findings from KEYTRUDA trial in advanced pleural mesothelioma presented at AACR 2015
20 April 2015 | By Victoria White
The first presentation of data investigating the use of KEYTRUDA in 25 patients with advanced pleural mesothelioma was made at AACR 2015...
article
The scope of PAT in real-time advanced control of tablet quality
20 April 2015 | By Ravendra Singh, Marianthi Ierapetritou and Rohit Ramachandran: Rutgers University
Continuous pharmaceutical manufacturing together with process analytical technology (PAT) provides a suitable platform for automatic feed-forward/feed-back (FF/FB) control of the end product quality as desired by quality by design (QbD)-based efficient manufacturing. The precise control of the quality of the pharmaceutical product requires proactive, corrective actions on the process/raw material…
news
UMC Utrecht’s new liver cancer treatment approved for use in Europe
14 April 2015 | By Victoria White
A new liver cancer treatment developed by the UMC Utrecht that uses uses radioactive holmium microspheres has received the European CE mark...
news
FDA grants Breakthrough Therapy Designation for Viaskin Peanut for the treatment of peanut allergy in children
13 April 2015 | By Victoria White
DBV Technologies has announced that the FDA has granted Breakthrough Therapy Designation to Viaskin Peanut for children with peanut allergies...
news
Inovio’s INO-3112 DNA immunotherapy shows positive preliminary results
9 April 2015 | By Victoria White
INO-3112 DNA immunotherapy has generated strong T cell responses in patients with head and neck cancer associated with human papillomavirus (HPV)...
news
Exelixis’ cabozantinib granted Fast Track designation by FDA for advanced renal cell carcinoma
9 April 2015 | By Victoria White
Exelixis has announced that the FDA has granted Fast Track designation to cabozantinib for treatment of patients with advanced renal cell carcinoma...
